MedTrace Logo

Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression

NCT00808769 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-06-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression.

Conditions

  • Normal Healthy Subject Population

Interventions

DRUG

Zegerid®

capsule(20 mg omeprazole/sodium bicarbonate), single dose

DRUG

Prilosec OTC®

Omeprazole-magnesium 20.6 mg, tablet, single dose

Sponsors & Collaborators

  • Procter and Gamble

    lead INDUSTRY

Principal Investigators

  • John McRorie, PhD, FACG, AGAF · Procter and Gamble

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00808769 on ClinicalTrials.gov